Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Biosimilar Monoclonal Antibodies Market Size And Revenue Outlook Through 2030
The biosimilar monoclonal antibodies market has shown substantial growth in recent years. It is anticipated to expand from $10.64 billion in 2025 to $11.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.2%. This historical development can be attributed to factors such as the high cost associated with originator biologics, the increasing incidence of chronic and autoimmune diseases, the expiration of patents for key monoclonal antibodies, rising healthcare expenditure, and a gradual improvement in regulatory clarity for biosimilars.
The biosimilar monoclonal antibodies market is projected to experience substantial expansion in the coming years. This market is predicted to reach a value of $14.58 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period is attributable to several factors, including the expansion of biosimilar pipelines, an escalating demand for accessible biologic treatments, a rise in approvals within developing markets, continuous progress in biopharmaceutical manufacturing, and supportive governmental policies encouraging biosimilar adoption. Key trends anticipated for this period encompass a growing acceptance of cost-effective biosimilar monoclonal antibodies, their increased application in treating oncology and autoimmune conditions, enhanced acceptance by both physicians and patients, broader regulatory approvals across international markets, and an intensified commitment to enhancing accessibility to biologic therapies.
Get A Free Sample Report With In-Depth Market Insights:
Biosimilar Monoclonal Antibodies Market Demand Drivers Opening New Revenue Streams
The increasing occurrence of autoimmune conditions is anticipated to drive expansion within the biosimilar monoclonal antibodies market in the coming period. These diseases represent a category of ailments where the body’s immune system erroneously assaults its own tissues and organs. The surge in autoimmune diseases is largely attributed to heightened environmental factors like pollution and chemicals, which can unbalance the immune system and foster unusual immune reactions. Biosimilar monoclonal antibodies contribute to tackling the growing prevalence of autoimmune diseases by offering affordable, potent, and readily available targeted treatments that regulate excessive immune responses in patients. For example, data from February 2024, provided by Arthritis Australia, an Australia-based non-profit organization, forecasts that in 2025, around 212,136 males and 362,137 females will be living with rheumatoid arthritis (RA). These figures are projected to climb by 2040, reaching approximately 280,040 males and 479,828 females. Consequently, the increasing frequency of autoimmune conditions is propelling the development of the biosimilar monoclonal antibodies market.
Biosimilar Monoclonal Antibodies Market Segmentation: How Does The Market Break Down By Category?
The biosimilar monoclonal antibodies market covered in this report is segmented –
1) By Type: Biopharmaceuticals, Other Types
2) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab
3) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications
Subsegments:
1) By Biopharmaceuticals: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Other Biopharmaceuticals
2) By Other Types: Antibody-Drug Conjugates, Fusion Proteins, Biosimilars Of Other Biologics
Biosimilar Monoclonal Antibodies Market Trends Powering Strategic Industry Growth
Key players in the biosimilar monoclonal antibody market are developing biosimilar versions of monoclonal antibodies with the goal of presenting economical alternatives to existing monoclonal antibody therapies, thus improving healthcare access and affordability. An intravenous formulation refers to an antibody preparation designed for direct delivery into the bloodstream through a vein, ensuring a swift therapeutic effect. For example, in May 2024, Bio-Thera Solutions, a China-based biopharmaceutical company, and Biogen Inc., a US-based biopharmaceutical company, launched TOFIDENCE (tocilizumab-bavi) in an intravenous formulation within the United States. The U.S. Food and Drug Administration had approved TOFIDENCE in September 2023 for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. At its launch, TOFIDENCE is accessible in three vial sizes: 80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL for intravenous infusion, with subcutaneous formulations anticipated for future release.
Biosimilar Monoclonal Antibodies Market Competitive Overview And Top Companies
Major companies operating in the biosimilar monoclonal antibodies market are Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy’s Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limited, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc.
View The Full Biosimilar Monoclonal Antibodies Market Report:
Biosimilar Monoclonal Antibodies Market Regional Analysis And Leading Geography
North America was the largest region in the biosimilar monoclonal antibodies market in 2025. The regions covered in the biosimilar monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
